Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiagnoCure licenses next-gen uPM3 to Gen-Probe

This article was originally published in The Gray Sheet

Executive Summary

Co-development pact for urine-based prostate cancer diagnostic, focusing on the PCA3 (DD3) genetic marker, corresponds with Gen-Probe's plan to broaden nucleic acid test offerings, CEO Henry Nordhoff says in Nov. 20 release. Gen-Probe will pay $3 mil. upfront to DiagnoCure, plus additional payments of up to $7.5 mil. DiagnoCure also will collect royalties of 8% on net product sales of up to $5 mil., and royalties of 16% on sales above $50 mil. "The test may offer advantages over prostate specific antigen (PSA) testing," the release notes...

You may also be interested in...



Gen-Probe’s PCA3 Prostate Cancer Test Could Be Alternative To Biopsy

Gen-Probe will seek approval for its PCA3 urine-based prostate cancer diagnostic as an alternative to the standard regimen of costly, invasive repeat biopsies for men who have abnormal PSA levels but test negative for cancer

Gen-Probe/DiagnoCure

136-patient study assessing DiagnoCure's urine-based prostate cancer diagnostic incorporating the PCA3/DD3 genetic marker shows sensitivity of 67%, specificity of 83% and negative predictive value of 90%, according to the Canadian firm. Study results were presented during the American Urological Association meeting in San Antonio May 22-26. The PCA3 assay is licensed to Gen-Probe (1"The Gray Sheet" Nov. 24, 2003, In Brief)...

Gen-Probe Cultivates Cancer Segment Through Roche HPV DNA Probe Deal

A supply and purchase agreement with Roche Molecular Systems for human papillomavirus DNA probes could enable Gen-Probe's fledgling oncology segment to introduce an HPV diagnostic in the U.S. by 2009, CEO Henry Nordhoff stated
UsernamePublicRestriction

Register

MT019359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel